US Stock MarketDetailed Quotes
RGLS Regulus Therapeutics
- 1.6400
- +0.1100+7.19%
Close Nov 27 16:00 ET
- 1.6300
- -0.0100-0.61%
Pre 08:00 ET
107.42MMarket Cap-1607P/E (TTM)
1.6550High1.5200Low315.23KVolume1.5400Open1.5300Pre Close505.61KTurnover0.65%Turnover RatioLossP/E (Static)65.50MShares3.790052wk High1.24P/B79.81MFloat Cap1.080052wk Low--Dividend TTM48.66MShs Float3071.9974Historical High--Div YieldTTM8.82%Amplitude0.7600Historical Low1.6030Avg Price1Lot Size
Regulus Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -50.53%-9.45M | -86.13%-11.64M | -7.74%-8.74M | -4.87%-26.77M | 2.05%-6.13M | 6.77%-6.28M | -1.51%-6.25M | -27.16%-8.11M | -5.79%-25.53M | 20.15%-6.25M |
| Net income from continuing operations | -79.73%-14.06M | -57.36%-11.04M | -18.63%-8.47M | -6.05%-30.04M | -18.63%-8.06M | -3.62%-7.82M | 3.38%-7.01M | -6.25%-7.14M | -1.85%-28.32M | 4.74%-6.8M |
| Depreciation and amortization | 60.71%90K | 89.36%89K | 68.75%81K | 86.07%227K | 130.30%76K | 75.00%56K | 51.61%47K | 84.62%48K | -73.42%122K | -19.51%33K |
| Other non cash items | --0 | -80.00%10K | 3.23%32K | 6.02%141K | -12.50%28K | 3.23%32K | 56.25%50K | -18.42%31K | 189.13%133K | 357.14%32K |
| Change In working capital | 401.68%2.69M | -758.16%-1.86M | -6.61%-1.5M | -53.27%257K | 297.18%846K | 25.76%537K | -55.66%282K | -93.94%-1.41M | -39.82%550K | 115.03%213K |
| -Change in receivables | ---- | --0 | --0 | ---- | ---- | ---- | -87.50%1K | 50.00%-4K | ---- | ---- |
| -Change in prepaid assets | 852.48%1.52M | -1,370.39%-1.93M | -33.48%445K | 856.72%507K | 87.11%-112K | -7.45%-202K | -50.81%152K | -1.76%669K | -180.72%-67K | 13.53%-869K |
| -Change in payables and accrued expense | 188.03%674K | 1,174.39%881K | 103.34%20K | -247.88%-698K | -170.97%-252K | -25.71%234K | -159.42%-82K | -633.93%-598K | 258.92%472K | 94.81%-93K |
| -Change in other current liabilities | 36.14%-53K | -433.94%-1.46M | 45.62%-149K | -1,290.00%-238K | -42.63%393K | -692.86%-83K | 19.17%-274K | 19.41%-274K | -72.60%20K | -14.59%685K |
| -Change in other working capital | -5.47%553K | 35.46%657K | -51.29%-1.82M | 448.80%686K | 66.73%817K | 104.55%585K | -6.73%485K | -2.56%-1.2M | -77.36%125K | -15.08%490K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -50.53%-9.45M | -86.13%-11.64M | -7.74%-8.74M | -4.87%-26.77M | 2.05%-6.13M | 6.77%-6.28M | -1.51%-6.25M | -27.16%-8.11M | -5.79%-25.53M | 20.15%-6.25M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 442.72%18.64M | -83K | -623.66%-78.54M | 195.84%14.49M | -52.88%4.93M | 57.70%-5.44M | 0 | 14,804.90%15M | -5,923.90%-15.12M | 25,629.27%10.47M |
| Net PPE purchase and sale | 94.82%-28K | ---83K | -22,800.00%-229K | -68.98%-610K | -7.94%-68K | -17,933.33%-541K | --0 | 99.02%-1K | -43.82%-361K | -53.66%-63K |
| Net investment purchase and sale | 481.14%18.67M | --0 | -622.10%-78.32M | 202.32%15.1M | -52.52%5M | 61.90%-4.9M | --0 | --15M | ---14.76M | --10.53M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 442.72%18.64M | ---83K | -623.66%-78.54M | 195.84%14.49M | -52.88%4.93M | 57.70%-5.44M | --0 | 14,804.90%15M | -5,923.90%-15.12M | 25,629.27%10.47M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -80.49%56K | -105.63%-744K | 11,665.84%93.11M | 163.10%11.82M | -873K | -93.61%287K | 13.21M | -40,350.00%-805K | -91.64%4.49M | 0 |
| Net issuance payments of debt | --0 | 33.29%-551K | 0.00%-826K | ---3.3M | ---826K | ---826K | ---826K | ---826K | --0 | --0 |
| Net common stock issuance | -94.97%56K | -101.38%-194K | 447,180.95%93.93M | 236.67%15.12M | ---47K | -75.21%1.11M | --14.03M | 950.00%21K | -91.65%4.49M | --0 |
| Proceeds from stock option exercised by employees | --0 | --1K | --2K | ---- | ---- | --0 | --0 | --0 | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -80.49%56K | -105.63%-744K | 11,665.84%93.11M | 163.10%11.82M | ---873K | -93.61%287K | --13.21M | -40,350.00%-805K | -91.64%4.49M | --0 |
| Net cash flow | ||||||||||
| Beginning cash position | -53.96%17.18M | -2.38%29.65M | -1.90%23.83M | -59.81%24.29M | 28.98%25.9M | 6.09%37.33M | -43.72%30.37M | -59.81%24.29M | 94.44%60.45M | -44.09%20.08M |
| Current changes in cash | 180.94%9.25M | -279.21%-12.46M | -4.29%5.82M | 98.72%-461K | -149.03%-2.07M | 24.33%-11.43M | 137.03%6.96M | 193.81%6.08M | -223.15%-36.16M | -82.82%4.21M |
| End cash Position | 2.09%26.44M | -53.96%17.18M | -2.38%29.65M | -1.90%23.83M | -1.90%23.83M | 28.98%25.9M | 6.09%37.33M | -43.72%30.37M | -59.81%24.29M | -59.81%24.29M |
| Free cash flow | -39.00%-9.48M | -87.46%-11.72M | -10.55%-8.97M | -5.77%-27.38M | 1.90%-6.2M | -1.22%-6.82M | 1.57%-6.25M | -25.17%-8.12M | -6.19%-25.89M | 19.77%-6.32M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data